Tirzepatide Pen 30mg / 2.4ml

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It enhances insulin secretion in a glucose-dependent manner, reduces appetite through central pathways and slows gastric emptying; the SURMOUNT-1 trial (NEJM 2022) reported mean weight reduction above 20% at the highest dose over 72 weeks.

It is the reference compound for metabolic and weight-management protocols, with weekly dosing and stepwise titration.

Presentation

• Format: Pre-filled injection pen
• Strength: 30mg / 2.4ml
• Storage: refrigerate at 2–8 °C; keep away from light

Supplied to healthcare professionals and their patients for use under medical supervision. Product information is educational and does not replace clinical judgement.